Design Therapeutics Q3 2024 GAAP EPS $(0.23) Beats $(0.31) Estimate
Benzinga Newsdesk 2 years ago
EarningsEarnings BeatsNews
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.31) by 25.81 percent.
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.31) by 25.81 percent.